PDF下载 ( 1579 KB)
Recent advances in targeted drug therapy for hepatocellular carcinoma
-
摘要:
靶向药物对于肝细胞癌的治疗效果在临床上已经被广泛证实。随着科学技术的发展,越来越多的靶向药物相继出现。近期,瑞格菲尼、ramucirumab等靶向药物在相应的临床实验中也表现出了相当的潜力。更多的二线候选药物,比如c-Met抑制剂tivantinib与cabozantinib、VEGFR-2抑制剂ramuciruma临床试验正在进行。总结了近几年靶向药物治疗肝细胞癌的试验数据及最新进展,为下一步临床试验及治疗提供参考意见。
Abstract:More and more clinical trials have proved the efficacy of targeted drugs in the treatment of hepatocellular carcinoma (HCC) .With the development of science and technology, more and more targeted drugs have appeared.In recent years, targeted drugs such as regorafenib and ramucirumab have shown great potential in related clinical trials.In addition, there are ongoing clinical trials for second-line candidate drugs, such as c-Met inhibitors tivantinib and cabozantinib and a VEGFR-2 inhibitor ramucirumab.This article summarizes the advances in targeted drug therapy for HCC and related trial data, which provides a reference for further clinical trials and treatment.
-
Key words:
- carcinoma, hepatocellular /
- targeted drug /
- drug therapy /
- clinical trial /
- review
-
[1]CHEN WQ, ZHENG RS, ZHANG SW, et al.Report of cancer incidence and mortality in China, 2013[J].China cancer, 2017, 26 (1) :1-7. (in Chinese) 陈万青, 郑荣寿, 张思维, 等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2017, 26 (1) :1-7. [2]THOMAS MB, CHADHA R, GLOVER K, et al.Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma[J].Cancer, 2007, 110 (5) :1059-1067. [3]KASEB AO, GARRETTMAYER E, MORRIS JS, et al.Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome:final results of a phase II trial[J].Oncology, 2012, 82 (2) :67-74. [4]HSU CH, KANG YK, YANG TS, et al.Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma:a multicenter phase II study[J].Oncology, 2013, 85 (1) :44-52. [5]THOMAS MB, MORRIS JS, CHADHA R, et al.Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma[J].J Clin Oncol, 2009, 27 (6) :843-850. [6]PHILIP A, PHILIP MD, HOLEN KD, et al.Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer[J].Cancer, 2012, 118 (9) :2424-2430. [7]THOMAS Y, HILDA W, CHAN P, et al.Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease[J].Invest New Drugs, 2012, 30 (6) :2384-2390. [8]ZHAO RR, DENG YD, YUAN H.Epidemiological and clinical features of primary cancan:ananalys of 236 patients[J].J Clin Hepatol, 2016, 32 (8) :1538-1542. (in Chinese) 赵荣荣, 邓永东, 袁宏.236例原发性肝癌患者流行病学及临床特点分析[J].临床肝胆病杂志, 2016, 32 (8) :1538-1542. [9]ASNACIOS A, FARTOUX L, ROMANO O, et al.Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma:results of a multicenter phase 2 study[J].Cancer, 2008, 112 (12) :2733-2739. [10]HANNA K, STEPHEN I, CHARD M, et al.Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma[J].Gastrointest Cancer Res, 2011, 4 (3) :78-83. [11]KANG YK, YAU T, PARK JW, et al.Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma[J].Ann Oncol, 2015, 26 (12) :2457-2463. [12]CHAN SL, YEO W, MO F, et al.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma[J].Cancer, 2017, 123 (20) :3977-3985. [13]ZHU AX, FINN RS, MULCAHY M, et al.A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer[J].Clin Cancer Res, 2013, 19 (23) :6614-6623. [14]ZHU AX, PARK J, RYOO BY, et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH) :a randomized, double-blind, multicenter, phase 3 trial[J].Lancet Oncol, 2015, 16 (7) :859-870. [15]ZHU AX, ANCUKIEWICZ M, SUPKO JG, et al.Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma:a phase II study[J].Clin Cancer Res, 2013, 19 (6) :1557-1566. [16]QIN SK.Apatinib in Chinese patients with advanced hepatocellular carcinoma:a phase II randomized, open-label trial[J].J Clin Oncol, 2014, 32 (15) :17-20. [17]LU W, JIN XL, YANG C, et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:a single-center randomized controlled trial[J].Cancer Biol Ther, 2017, 18 (6) :433-438. [18]LLOVET JM, RICCI S, MAZZAFERRO V, et al.SHARP Investigators Study Group.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390. [19]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34. [20]JACKSON R, PSARELLI EE, BERHANE S, et al.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer:a Meta-analysis of randomized phase III trials[J].J Clin Oncol, 2017, 35 (6) :622-628. [21]WANG Y, WANG MQ, DUAN F.Prognostic factor analysis of moderate-advanced hepatocellular carcinoma treated with sorafenib[J].J Intervent Radiol, 2017, 26 (3) :258-262. (in Chinese) 王燕, 王茂强, 段峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介人放射学杂志, 2017, 26 (3) :258-262. [22]TAKAHASHI H, NASU K, MINAMI M, et al.Organ atrophy induced by sorafenib and sunitinib-quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen[J].Pol J Radiol, 2016, 81:557-565. [23]XU L, ZHOU DS, ZHAO J, et al.Long-term therapy with sorafenib is associated with pancreatic atrophy[J].J Surg Res, 2015, 199 (2) :314-321. [24]PATT Y, ROJAS-HERNANDEZ C, EKRAZAD HM, et al.Phase II trial of sorafenib in combination with capecitabine in patients with hepatocellular carcinoma:INST 08-20[J].Oncologist, 2017, 22 (10) :1158-e116. [25]BRUIX J, TAK WY, GABARRINI A, et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:multicenter, open-label, phase II safety study[J].Eur J Cancer, 2013, 49 (16) :3412-3419. [26]BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) :a randomized, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2017, 389 (10064) :56-66. [27]IKEDA M, OKUSAKA T, MITSUNAGA S, et al.Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2016, 22 (6) :1385-1394. [28]IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].J Gastroenterol, 2017, 52 (4) :512-519. [29]ZHUAX, KUDO M, ASSENAT E, et al.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial[J].JAMA, 2014, 312 (1) :57-67. [30]SANOFF HK, KIM R, LVANOVA A, et al.Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma[J].Invest New Drugs, 2015, 33 (2) :505-509. [31]SANTORO A, RIMASSA L, BORBATH I, et al.Tivantinib for second-line treatment of advanced hepatocellular carcinoma:a randomised, lacebo-controlled phase 2 study[J].Lancet Oncol, 2013, 14 (1) :55-63. [32]KELLEY RK, VERSLYPE C, COHN AL, et al.Cabozantinib in hepatocellular carcinoma:results of a phase 2 placebo-controlled randomized discontinuation study[J].Ann Oncol, 2017, 28 (3) :528-534. [33]SANDRINE JF, ARMANDO S, ROBIN KK, et al.A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY) , in patients with advanced hepatocellular carcinoma (HCC) [J].J Clin Oncol, 2014, 32 (Suppl 3) :lba173. [34]CAO Y, AGARWAL R, DITURI F, et al.NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-βreceptor blocker galunisertib in HCC[J].Cell Death Dis, 2017, 8 (2) :e2634. [35]FAN J, ZHOU J, YANG XR.Surgical treatment of hepatocellular carcinoma in the precision medicine era[J].Chin J Dig Surg, 2017, 16 (1) :22-27. (in Chinese) 樊嘉, 周俭, 杨欣荣.精准医学时代的肝癌外科治疗[J].中华消化外科杂志, 2017, 16 (1) :22-27. 期刊类型引用(13)
1. 温芳芳，张龙，王娟. 预后营养指数、血清白蛋白对肝切除术病人术后感染风险的预测价值及护理指导意义. 全科护理. 2025(02): 236-239 . 
百度学术2. 魏红艳，王远珍，常丽仙，木唤，刘春云，刘立. 原发性肝癌合并腹水患者发生SBP的风险预测分析. 昆明医科大学学报. 2024(03): 133-140 . 百度学术3. 魏红艳，王远珍，常丽仙，木唤，刘春云，刘立. 原发性肝癌患者并发自发性腹膜炎临床诊断模型的构建和应用. 现代肿瘤医学. 2024(19): 3718-3725 . 百度学术4. 朱明强，杨大帅，熊祥云，裴俊鹏，彭阳，丁佑铭. 肝癌肝切除术后感染风险预测模型的建立与评价. 临床肝胆病杂志. 2023(01): 110-117 . 
本站查看5. 罗清兰，邓宇伟，曾涛. 原发性肝癌术前中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和甲胎蛋白对预后的评估分析. 当代医学. 2022(19): 18-21 . 百度学术6. 付先锋，晏燕. 肝动脉介入栓塞治疗的肝癌患者预后与血清胆碱酯酶、钠水平的关系分析. 检验医学与临床. 2022(24): 3417-3420 . 百度学术7. 曾桥. 腹腔镜手术治疗肝癌的分析. 当代医学. 2021(04): 96-98 . 百度学术8. 黄旦华. 多项肿瘤标志物联合检测在肝癌中的诊断效能. 医疗装备. 2021(11): 52-53 . 百度学术9. 袁维，孙克伟，陈斌，朱文芳，银思涵. 56例中晚期原发性肝癌死亡患者的临床分析. 中西医结合肝病杂志. 2021(08): 707-711 . 百度学术10. 马冰，白黎，赵艳，海丹丹，李花花. 原发性肝癌TACE术后发生感染性并发症的影响因素研究. 实用癌症杂志. 2021(12): 2033-2035 . 百度学术11. 王益卓，刘唯佳，卢兵，黄其密，唐德奉. 原发性肝癌合并肺部感染58例临床特征分析. 中华肺部疾病杂志(电子版). 2020(01): 83-84 . 百度学术12. 刘娟. 以坚强概念为基础的心理干预对原发性肝癌合并抑郁病人症状改善、心理状态及生命质量的影响. 全科护理. 2020(28): 3834-3837 . 百度学术13. 叶颖剑，刘波，陈伟，李琼霞. 血清AFP阴性的肝细胞癌患者预后及分期系统分析. 临床肝胆病杂志. 2019(03): 535-541 . 本站查看其他类型引用(4)
-
百度学术
下载:
